1-primary-large-dark.jpg
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
16 sept. 2024 07h00 HE | Abata
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
1-primary-large-dark.jpg
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
22 août 2024 07h00 HE | Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
1-primary-large-dark.jpg
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
15 août 2024 07h00 HE | Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
1-primary-large-dark.jpg
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
09 juil. 2024 06h00 HE | Abata
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis